Jan 3 (Reuters) - Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.69 USD | -2.24% | -6.60% | +46.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.79% | 1.86B | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.52% | 21.58B | |
-9.77% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios' blood disorder drug meets goals of late-stage study